COORDINATE-Diabetes试验:干预改善糖尿病合并心血管疾病循证照护在不同性别、种族和族裔亚组中的效果
COORDINATE-Diabetes试验的二次分析评估了多层面、基于诊所的干预在2型糖尿病合并动脉粥样硬化性心血管疾病患者中增加循证药物处方的效果是否因性别、种族和族裔而异。结果显示,干预组在女性、黑人和西班牙裔参与者中所有3类药物处方比例均绝对增加,且性别、种族和族裔间的交互作用无统计学意义。结论认为该干预能一致改善循证照护的提供,不受性别、种族或族裔影响。
要点
- 干预使女性、黑人和西班牙裔参与者接受全部3类循证治疗的比例绝对提高。
- 广泛推广该干预可能改善医疗质量公平性,尤其对临床试验中代表性不足的人群。
核心结论
- COORDINATE-Diabetes干预成功改善了循证照护的提供,且效果不受性别、种族或族裔影响。
研究设计与样本
- COORDINATE-Diabetes是一项整群随机试验,从美国43个心脏病诊所招募参与者(20个随机分配至干预组,23个至常规照护组)。
- 本分析为预设二次分析,纳入1045例2型糖尿病合并动脉粥样硬化性心血管疾病参与者,中位年龄70岁,32%为女性,16%为黑人,9%为西班牙裔。
- 主要结局为末次试验评估(6至12个月)时处方全部3类循证治疗(高强度他汀、ACEI/ARB、SGLT2i或GLP-1RA)的参与者比例。
- 采用混合效应逻辑回归模型,按自我报告的性别、种族和族裔评估干预组与常规照护组的结局,并调整基线特征、药物、合并症和站点位置。
主要发现
- 末次评估时,干预组与常规照护组相比,女性中处方全部3类治疗的比例绝对增加(36% vs 15%)。
- 黑人参与者中干预组与常规照护组比例为41% vs 18%,西班牙裔参与者中为46% vs 18%。
- 性别间交互作用P=0.44,种族间交互作用P=0.59,族裔间交互作用P=0.78,均无统计学意义。
关键数值与推荐
- 主要结局为处方全部3类循证治疗(高强度他汀、ACEI/ARB、SGLT2i或GLP-1RA)的参与者比例。
- 女性:干预组36% vs 常规照护组15%;黑人:41% vs 18%;西班牙裔:46% vs 18%。
- 交互作用P值:性别P=0.44,种族P=0.59,族裔P=0.78。
临床怎么用
- 多层面、基于诊所的干预可有效增加2型糖尿病合并动脉粥样硬化性心血管疾病患者的循证药物处方。
- 干预效果在女性、黑人和西班牙裔人群中一致,支持在该类人群中推广以改善医疗公平性。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Results from the COORDINATE-Diabetes trial (Coordinating Cardiology Clinics Randomized Trial of Interventions to Improve Outcomes - Diabetes) demonstrated that a multifaceted, clinic-based intervention increased prescription of evidence-based medical therapies to participants with type 2 diabetes and atherosclerotic cardiovascular disease. This secondary analysis assessed whether intervention success was consistent across sex, race, and ethnicity. METHODS: COORDINATE-Diabetes, a cluster randomized trial, recruited participants from 43 US cardiology clinics (20 randomized to intervention and 23 randomized to usual care). The primary outcome was the proportion of participants prescribed all 3 groups of evidence-based therapy (high-intensity statin, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, and sodium-glucose cotransporter-2 inhibitor or glucagon-like peptide 1 receptor agonist) at last trial assessment (6 to 12 months). In this prespecified analysis, mixed-effects logistic regression models were used to assess the outcome by self-reported sex, race, and ethnicity in the intervention and usual care groups, with adjustment for baseline characteristics, medications, comorbidities, and site location. RESULTS: Among 1045 participants with type 2 diabetes and atherosclerotic cardiovascular disease, the median age was 70 years, 32% were female, 16% were Black, and 9% were Hispanic. At the last trial assessment, there was an absolute increase in the proportion of participants prescribed all 3 groups of evidence-based therapy in women (36% versus 15%), Black participants (41% versus 18%), and Hispanic participants (46% versus 18%) with the intervention compared with usual care, with consistent benefit across sex (male versus female; Pinteraction=0.44), race (Black versus White; Pinteraction=0.59), and ethnicity (Hispanic versus Non-Hispanic; Pinteraction= 0.78). CONCLUSIONS: The COORDINATE-Diabetes intervention successfully improved delivery of evidence-based care, regardless of sex, race, or ethnicity. Widespread dissemination of this intervention could improve equitable health care quality, particularly among women and minority communities who are frequently underrepresented in clinical trials. REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03936660.
引用
- Tannu M, Kaltenbach L, Pagidipati NJ, et al. Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial. Circulation. 2024. PMID: 38934111. doi:10.1161/CIRCULATIONAHA.124.068962
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。